{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:13:05Z","timestamp":1761894785448,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.3816\/ccc.2006.n.040","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:06:03Z","timestamp":1221080763000},"page":"224-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Ocular Toxicity Related to Cetuximab Monotherapy in Patients with Colorectal Cancer"],"prefix":"10.3816","volume":"6","author":[{"given":"Shelley","family":"Dranko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie","family":"Kinney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh K.","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2006.n.040_bib1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/dji104","article-title":"Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient","volume":"97","author":"Tonini","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CCC.2006.n.040_bib2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"year":"2004","series-title":"Erbitux\u2122 [package insert]","key":"10.3816\/CCC.2006.n.040_bib3"},{"key":"10.3816\/CCC.2006.n.040_bib4","unstructured":"Gustafson NF, Saltz L, Cunningham D, et al. Safety profile of cetuximab in patients with metastatic colorectal cancer. Presented at: American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium; January 2004; San Francisco, CA. Abstract #237."},{"key":"10.3816\/CCC.2006.n.040_bib5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.040_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2006.n.040_bib7","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/annonc\/mdi300","article-title":"Trichomegaly of the eyelashes following treatment with cetuximab","volume":"16","author":"Bouche","year":"2005","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2006.n.040_bib8","first-page":"2695","article-title":"Eyelid disorders: diagnosis and management","volume":"57","author":"Carter","year":"1998","journal-title":"Am Fam Physician"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811702870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811702870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:59:31Z","timestamp":1761519571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811702870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S1533002811702870"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2006.n.040","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2006,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Toxicity Related to Cetuximab Monotherapy in Patients with Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2006.n.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}